Fitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012

Transcription

1 Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012

2 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care 2

3 One Size Fits All Approach Generates vastly different patient outcomes + + = Different outcomes Patients Disease Treatment Different treatment outcomes affect patient outcomes, quality of life and safety. 3

4 Personalized Healthcare (PHC) The right therapy for the right group of patients at the right time Group of patients with the same syndrome Targeted therapy 4

5 Today s Challenge Drugs Don t Always Work Patients response rates to major drugs in selected therapeutic areas can be very different Analgesics 80% Asthma 60% Cardiac Arrhythmias 60% Diabetes 57% Migraine 50% Oncology 25% Osteoporosis 48% Spear, B. et al.: Clinical application of pharmacogenetics. Trends in Molecular Medicine 2001; 7:

6 PHC Helps Predict Individual Response to Therapy Identifying patients who will benefit from therapy reduces risk for devastating endpoints Monitor Response Predict Response Directing Patient Therapy Individual Response Does drug(s) work for the patient? Cholesterol (LDL) HbA1c/Glucose Biomarker as surrogate LDL < 130 mg/ml HbA1c < 7% Genetic Disposition Genomic testing for therapeutic response Clopidogrel Warfarin Predict patient response Ensure consistent level of efficacy for all patients Companion Identify patients with specific mutations Metastatic melanoma/ cobas BRAF V600 Mutation test Breast cancer/ HER2 companion test Directing patient therapy with a specific pharmaceutical Clinical Endpoints Infarction, Death CVD, Kidney damage Clinical Endpoints Infarction vs. bleeding Stroke vs. bleeding Clinical Endpoints Improve benefit-risk ratio of treatment 6

7 PHC benefits all stakeholders in healthcare Patients Best treatment Physicians & Providers Optimize therapy Minimize adverse events Payers & Reimbursers Longer life, improved function Reduced resource utilization Better targeting of expensive therapies PHC Regulators & Policy Makers Avoid unnecessary care 7

8 The Practical Value of PHC Human Papilloma Virus genotyping - the link to cervical cancer. Genomics improving diagnosis and therapy. Helping to answer the difficult questions The Patient What do I have? What caused it? What explains my symptoms? What are my prospects? Has it spread? What is my treatment? Will I be cured? Will I be hurt? How will I be followed? Will it return? Will others in my family get it? The Doctor Diagnosis Etiology: Infections/Genetic Pathogenesis Prognosis Metastasis Therapeutic Targets Response Prediction Toxicity Prediction Monitoring Relapse Predisposition Screening 8

9 Synergy Pharmaceuticals & working together to deliver powerful market solutions Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care 9

10 Roche Demonstrates Industry Leadership A unique symbiosis driving innovation Companion in development Active projects resulting from collaborations between Roche Pharma and 10

11 Roche PHC Solutions Available Today From screening and diagnosis to therapy selection and monitoring, Roche is providing solutions for improved patient care Oncology Breast and stomach cancer: Herceptin and HER2-positive patients Metastatic Melanoma: Zelboraf and BRAF V600E positive patients Tumor markers for cancer screening Infectious Disease Low level viremia monitoring for Hepatitis B and C infections HIV viral load monitoring HPV genotyping and cervical cancer Cardiovascular Cardiac markers for diagnosis of acute coronary syndrome and CHF Monitoring warfarin therapy through patient self-testing Glucose and HbA1c testing for patients with Diabetes 11

12 Personalized Health Care Making a Difference - One Person at a Time Kristen s story 12

13 Personalized Healthcare a key enabler Roche: world-class science to benefit patients We create and commercialise medically differentiated products and services that lead to tangible improvements in the health, quality of life and survival of patients. 13

14 We Innovate Healthcare